Arnatar Secures Over $50 Million in Series A Financing to Advance Nucleic Acid Therapeutics Pipeline

The proceeds of this fundraising will be mainly used to accelerate the in-depth layout of the company's drug pipeline, rapidly advance clinical trials, and support the operational establishment of the company in China.

Arnatar was founded in 2022 by a global team of scientists in the field of nucleic acid drugs.Has built a breakthrough innovative nucleic acid drug platform and continues to explore new mechanisms of nucleic acid-based drugs, covering multiple therapeutic areas.。

According to the introduction on Arnatar's official website, the company is leveraging innovative Antisense Technology and utilizingRNA Interference (RNAi) and Antisense Oligonucleotide (ASO) PlatformsRegulate the expression of target genes, thereby providingLiver, Extrahepatic Organ Diseases, and Common/Rare DiseasesProvides opportunities for treatment.

RNAi is a method of gene silencing mediated by double-stranded RNA.Some of these target specific genes in a sequence-dependent manner and suppress their expression, known as siRNA. As a new technological drug that has emerged in recent years, siRNA drugs boast advantages such as multiple druggable targets, potent efficacy, good safety, low dosing frequency, and a wide range of indications, making them one of the most promising frontier pharmaceutical fields globally.

ASOIs a single-stranded oligonucleotide molecule, after entering the cell, it binds to the target mRNA through sequence complementarity,Can lead to mRNA degradation, or alter mRNA splicing,Thereby achieving the effect of targeting the potential mechanisms of diseases at the mRNA level and treating diseases.。